SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing Palantirs sovereign-AI and customized-software opportunity, is fueling attention alongside the stocks move to new highs. Bulls are celebrating the breakout and speculating about short-covering, while bears argue the valuation is stretched and warn of a pullback.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares are under pressure after SpaceX agreed to acquire low-band spectrum to expand Starlink Mobile and potentially compete with wireless carriers. Traders are split between viewing the move as a long-term competitive threat and calling the selloff an overreaction given the infrastructure and time needed to challenge established networks.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs planned low-band spectrum acquisition for Starlink Mobile has fueled concerns that it could eventually compete with Verizon and pressure the wireless business, contributing to the sharp selloff. Traders are divided: some see the threat as distant given the infrastructure and regulatory hurdles and view the decline as an overreaction, while others worry about future customer losses and pricing pressure.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

A reported NIH push to accelerate personalized cancer-vaccine research has lifted vaccine and biotech shares, with traders linking BioNTechs oncology pipeline to the sector rally. Some see BNTX as a sympathy play, while others complain it has lagged Modernas stronger move.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

ADAs rebound has sparked breakout and altcoin-rotation chatter, with bullish traders citing partnership and adoption developments and anticipating further gains. Others see the move as a short-lived pump, pointing to ADAs past underperformance and uncertain crypto-market direction.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

DOTs sharp rebound toward the $1.30 resistance level has prompted technical breakout and short-squeeze speculation, with some traders pointing to Polkadot developments such as dotUSD and tokenomics changes as supporting context. Others see the move as a relief rally and remain bearish, citing DOTs steep longer-term decline and concerns about adoption and demand.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally and elevated volume have focused attention on Starknets privacy and Bitcoin DeFi developments, alongside its post-quantum security ambitions and possible shift toward an independent Layer 1. Traders are largely bullish on the momentum and technology narrative, while some remain wary of token unlocks and the risk that the move is a short-lived pump.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention for a breakout to record highs as traders point to continued momentum in software stocks and interest in AI-related observability. Bulls see the move as a continuation, while some traders warn that the valuation is stretched and watch for a reversal.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas sharp selloff is drawing attention amid concerns that elevated oil and jet-fuel costs, alongside uncertainty around Iran and the Strait of Hormuz, could pressure airline margins. Traders also debate whether short-selling and shares left over from the substantial issuer bid are outweighing buyback support, while bulls point to Aeroplans value and further repurchases as counterpoints.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks shares are drawing attention after its partnered personalized cancer vaccine with Moderna met Phase 3 recurrence-free and distant metastasis-free survival endpoints when combined with Keytruda, prompting optimism about oncology pipeline potential. Traders are debating whether the enthusiasm is justified before full results and overall-survival data, with Keytrudas approaching patent expiration also in focus.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder  

Equity

Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.


Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Key PointsChief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026...

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Key PointsCEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026...

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?

Key PointsCEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share...

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...

Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates

Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two ha...

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider directly...

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up   - Here's Why

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy...

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Maze Therapeutics Inc.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$MAZE  
10:29 AM 
Truist analyst Danielle Brill views Vertex's (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-mediated kidney disease and estimates the data supports a potential addressable population of greater than 100,000 patients. The firm, which sees the data having "a significant positive readthrough" for Maze Therapeutics (MAZE), adds that while it remains too early to draw conclusions regarding relative efficacy, it believes the size of the opportunity is large enough to support blockbuster sales potential for MZE829 even if it ultimately demonstrates efficacy and safety comparable to inaxaplin. Truist has a Buy rating and $64 price target on Maze shares, which are up about 25% to $28.00 in morning trading.

John Smith

Is $MAZE a buyout candidate? I know it’s too early to say but wondering what people thought.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MAZE Maze Therapeutics Inc.

Fundamentals

Latest MAZE News